About BiondVax

BiondVax is a publicly traded biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.

With 6 completed clinical trials, BiondVax is preparing for its first pivotal clinical efficacy Phase 3 trial.

In the News

Prof. Ruth Arnon interview [30 Aug 2017]


Israel21C thumbnailIs this the end of flu? Israel’s BiondVax develops universal flu vaccine” [18 Feb. 2016]

Join our Mailing List